Expand KURA Menu
KURA MENU

KURA Latest Press Releases

-- February 6, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- January 11, 2026 --

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones Globe Newswire 5:00 PM

-- January 5, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- December 8, 2025 --

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML Globe Newswire 10:30 AM

-- December 3, 2025 --

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Globe Newswire 8:32 AM

-- November 25, 2025 --

KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) Globe Newswire 5:16 PM

-- November 13, 2025 --

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Globe Newswire 10:51 AM

-- November 12, 2025 --

Kura Oncology to Participate in Upcoming Investor Conference Globe Newswire 4:05 PM

-- November 7, 2025 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- November 4, 2025 --

Kura Oncology Reports Third Quarter 2025 Financial Results Globe Newswire 6:31 AM

-- November 3, 2025 --

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin Globe Newswire 4:02 PM
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting Globe Newswire 9:14 AM

-- October 28, 2025 --

Kura Oncology to Report Third Quarter 2025 Financial Results Globe Newswire 4:01 PM

-- October 24, 2025 --

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin Globe Newswire 7:02 AM

-- October 18, 2025 --

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress Globe Newswire 3:23 AM

-- October 3, 2025 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- October 1, 2025 --

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Globe Newswire 7:01 AM

-- September 29, 2025 --

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) Globe Newswire 4:01 PM

-- September 25, 2025 --

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology Globe Newswire 5:18 PM

-- September 24, 2025 --

Kura Oncology to Participate in Upcoming Investor Conference Globe Newswire 7:30 AM

-- September 16, 2025 --

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes